Review ArticleReview

Overdiagnosis of breast cancer in population screening: does it make breast screening worthless?

Nehmat Houssami
Cancer Biology & Medicine February 2017, 14 (1) 1-8; DOI: https://doi.org/10.20892/j.issn.2095-3941.2016.0050

References

  1. 1.↵
    2. Nelson HD,
    3. Fu R,
    4. Cantor A,
    5. Pappas M,
    6. Daeges M,
    7. Humphrey L.
    Effectiveness of breast cancer screening: systematic review and meta-analysis to update the 2009 U.S. preventive services task force recommendation. Ann Intern Med. 2016; 164: 244–55.
    OpenUrlCrossRefPubMed
  2. 2.↵
    2. Lauby-Secretan B,
    3. Scoccianti C,
    4. Loomis D,
    5. Benbrahim-Tallaa L,
    6. Bouvard V,
    7. Bianchini F, et al.
    Breast-cancer screening–viewpoint of the IARC Working Group. N Engl J Med. 2015; 372: 2353–8.
    OpenUrlCrossRefPubMed
  3. 3.↵
    Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. Lancet. 2012; 380: 1778–86.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.
    2. Glasziou P,
    3. Houssami N.
    The evidence base for breast cancer screening. Prev Med. 2011; 53: 100–2.
    OpenUrlCrossRefPubMed
  5. 5.↵
    2. Nelson HD,
    3. Tyne K,
    4. Naik A,
    5. Bougatsos C,
    6. Chan BK,
    7. Humphrey L.
    Screening for breast cancer: an update for the U.S. preventive services task force. Ann Intern Med. 2009; 151: 727–37.
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    2. Rosenbaum L.
    Invisible risks, emotional choices–mammography and medical decision making. N Engl J Med. 2014; 371: 1549–52.
    OpenUrlCrossRefPubMed
  7. 7.↵
    2. Elmore JG,
    3. Fletcher SW.
    Overdiagnosis in breast cancer screening: time to tackle an underappreciated harm. Ann Intern Med. 2012; 156: 536–7.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.
    2. Barratt A.
    Overdiagnosis in mammography screening: a 45 year journey from shadowy idea to acknowledged reality. BMJ. 2015; 350: h867.
    OpenUrlFREE Full Text
  9. 9.
    2. Etzioni R,
    3. Xia J,
    4. Hubbard R,
    5. Weiss NS,
    6. Gulati R.
    A reality check for overdiagnosis estimates associated with breast cancer screening. J Natl Cancer Inst. 2014; 106:pii:dju315. DOI: 10.1093/jnci/dju315.
    OpenUrlCrossRefPubMed
  10. 10.
    2. Kerlikowske K.
    Progress toward consensus on breast cancer screening guidelines and reducing screening harms. JAMA Intern Med. 2015; 175: 1970–1.
    OpenUrl
  11. 11.
    2. Hubbard RA.
    US counties with higher rates of breast cancer screening have higher rates of incidence with no concomitant decrease in breast cancer mortality suggesting overdiagnosis. Evid Based Med. 2015; 20: 201.
    OpenUrl
  12. 12.↵
    2. Nelson HD,
    3. Pappas M,
    4. Cantor A,
    5. Griffin J,
    6. Daeges M,
    7. Humphrey L.
    Harms of breast cancer screening: systematic review to update the 2009 U.S. preventive services task force recommendation. Ann Intern Med. 2016; 164: 256–67.
    OpenUrlCrossRefPubMed
  13. 13.↵
    2. Houssami N,
    3. Miglioretti DL,
    2. Nelson HD,
    3. Humphrey L,
    4. Fu RW.
    Estimates of screening benefit: The randomized trials of breast cancer screening. In: Houssami N, Miglioretti DL, eds. Breast Cancer Screening: An Examination of Scientific Evidence.London, UK: Elsevier; 2016.
  14. 14.↵
    2. Harris R,
    3. Yeatts J,
    4. Kinsinger L.
    Breast cancer screening for women ages 50 to 69 years a systematic review of observational evidence. Prev Med. 2011; 53: 108–14.
    OpenUrlCrossRefPubMed
  15. 15.
    2. Coldman A,
    3. Phillips N.
    Population studies of the effectiveness of mammographic screening. Prev Med. 2011; 53: 115–7.
    OpenUrlPubMed
  16. 16.↵
    2. Schopper D,
    3. de Wolf C.
    How effective are breast cancer screening programmes by mammography? Review of the current evidence. Eur J Cancer. 2009; 45: 1916–23.
    OpenUrlCrossRefPubMedWeb of Science
  17. 17.↵
    2. Houssami N,
    3. Miglioretti DL
    2. Harris RP.
    The importance of observational evidence to estimate and monitor mortality reduction from current breast cancer screening. In: Houssami N, Miglioretti DL, eds. Breast Cancer Screening: An Examination of Scientific Evidence. London, UK: Elsevier; 2016.
  18. 18.↵
    2. Berry DA,
    3. Cronin KA,
    4. Plevritis SK,
    5. Fryback DG,
    6. Clarke L,
    7. Zelen M, et al.
    Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005; 353: 1784–92.
    OpenUrlCrossRefPubMedWeb of Science
  19. 19.↵
    2. Houssami N,
    3. Irwig L,
    4. Ciatto S.
    Radiological surveillance of interval breast cancers in screening programmes. Lancet Oncol. 2006; 7: 259–65.
    OpenUrlCrossRefPubMedWeb of Science
  20. 20.↵
    2. Nederend J,
    3. Duijm LE,
    4. Voogd AC,
    5. Groenewoud JH,
    6. Jansen FH,
    7. Louwman MWJ.
    Trends in incidence and detection of advanced breast cancer at biennial screening mammography in The Netherlands: a population based study. Breast Cancer Res. 2012; 14: R10.
    OpenUrlCrossRefPubMed
  21. 21.↵
    2. Carter JL,
    3. Coletti RJ,
    4. Harris RP.
    Quantifying and monitoring overdiagnosis in cancer screening: a systematic review of methods. BMJ. 2015; 350: g7773.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    2. Biesheuvel C,
    3. Barratt A,
    4. Howard K,
    5. Houssami N,
    6. Irwig L.
    Effects of study methods and biases on estimates of invasive breast cancer overdetection with mammography screening: a systematic review. Lancet Oncol. 2007; 8: 1129–38.
    OpenUrlCrossRefPubMedWeb of Science
  23. 23.
    2. de Gelder R,
    3. Heijnsdijk EAM,
    4. van Ravesteyn NT,
    5. Fracheboud J,
    6. Draisma G,
    7. de Koning HJ.
    Interpreting overdiagnosis estimates in population-based mammography screening. Epidemiol Res. 2011; 33: 111–21.
    OpenUrl
  24. 24.
    2. Morrell S,
    3. Barratt A,
    4. Irwig L,
    5. Howard K,
    6. Biesheuvel C,
    7. Armstrong B.
    Estimates of overdiagnosis of invasive breast cancer associated with screening mammography. Cancer Causes Control. 2010; 21: 275–82.
    OpenUrlCrossRefPubMedWeb of Science
  25. 25.↵
    2. Puliti D,
    3. Miccinesi G,
    4. Paci E.
    Overdiagnosis in breast cancer: design and methods of estimation in observational studies. Prev Med. 2011; 53: 131–3.
    OpenUrlCrossRefPubMed
  26. 26.↵
    2. Puliti D,
    3. Duffy SW,
    4. Miccinesi G,
    5. de Koning H,
    6. Lynge E,
    7. Zappa M, et al.
    Overdiagnosis in mammographic screening for breast cancer in Europe: a literature review. J Med Screen. 2012; 19 Suppl 1:42–56.
    OpenUrlCrossRefPubMed
  27. 27.↵
    2. Paci E,
    3. Broeders M,
    4. Hofvind S,
    5. Puliti D,
    6. Duffy SW,
    EUROSCREEN Working Group. European breast cancer service screening outcomes: a first balance sheet of the benefits and harms. Cancer Epidemiol Biomarkers Prev. 2014; 23: 1159–63.
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    2. Keating NL,
    3. Pace LE.
    New guidelines for breast cancer screening in US women. JAMA. 2015; 314: 1569–71.
    OpenUrlCrossRefPubMed
  29. 29.↵
    2. Mandelblatt JS,
    3. Stout NK,
    4. Schechter CB,
    5. van den Broek JJ,
    6. Miglioretti DL,
    7. Krapcho M, et al.
    Collaborative modeling of the benefits and harms associated with different U.S. breast cancer screening strategies. Ann Intern Med. 2016; 164: 215–25.
    OpenUrl
  30. 30.↵
    2. Hersch J,
    3. Barratt A,
    4. Jansen J,
    5. Irwig L,
    6. McGeechan K,
    7. Jacklyn G, et al.
    Use of a decision aid including information on overdetection to support informed choice about breast cancer screening: a randomised controlled trial. Lancet. 2015; 385: 1642–52.
    OpenUrlCrossRefPubMed
  31. 31.↵
    2. Barratt A,
    3. Howard K,
    4. Irwig L,
    5. Salkeld G,
    6. Houssami N.
    Model of outcomes of screening mammography: information to support informed choices. BMJ. 2005; 330: 936.
    OpenUrlAbstract/FREE Full Text
  32. 32.↵
    Canadian Task Force on Preventive Health Care. 2011. Accessed from: http://canadiantaskforce.ca/ctfphc-guidelines/2011-breast-cancer/risks-and-benefits-age-50%E2%80%9369/.
  33. 33.↵
    2. Houssami N,
    3. Miglioretti DL,
    2. Hersch J,
    3. Jansen J,
    4. McCaffery K.
    Informed and shared decision making in breast screening. In: Houssami N, Miglioretti DL, eds. Breast Cancer Screening: An Examination of Scientific Evidence. London, UK: Elsevier; 2016.
  34. 34.
    2. Mathieu E,
    3. Barratt A,
    4. Davey HM,
    5. McGeechan K,
    6. Howard K,
    7. Houssami N.
    Informed choice in mammography screening: a randomized trial of a decision aid for 70-year-old women. Arch Intern Med. 2007; 167: 2039–46.
    OpenUrlCrossRefPubMedWeb of Science
  35. 35.↵
    2. Mathieu E,
    3. Barratt AL,
    4. McGeechan K,
    5. Davey HM,
    6. Howard K,
    7. Houssami N.
    Helping women make choices about mammography screening: an online randomized trial of a decision aid for 40-year-old women. Patient Educ Couns. 2010; 81: 63–72.
    OpenUrlCrossRefPubMed
  36. 36.↵
    2. Houssami N,
    3. Miglioretti DL,
    2. Dixon JM,
    3. Cameron D.
    Treatment of screen-detected breast cancer: Can we avoid or minimize overtreatment? In: Houssami N, Miglioretti DL, eds. Breast Cancer Screening: An Examination of Scientific Evidence. London, UK: Elsevier; 2016.
  37. 37.
    2. Hubbard RA,
    3. Kerlikowske K,
    4. Flowers CI,
    5. Yankaskas BC,
    6. Zhu W,
    7. Miglioretti DL.
    Cumulative probability of false-positive recall or biopsy recommendation after 10 years of screening mammography: a cohort study. Ann Intern Med. 2011; 155: 481–92.
    OpenUrlCrossRefPubMedWeb of Science
  38. 38.
    2. Miller AB,
    3. Wall C,
    4. Baines CJ,
    5. Sun P,
    6. To T,
    7. Narod SA.
    Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. BMJ. 2014; 348: g366.
    OpenUrlAbstract/FREE Full Text
  39. 39.
    2. Zackrisson S,
    3. Andersson I,
    4. Janzon L,
    5. Manjer J,
    6. Garne JP.
    Rate of over-diagnosis of breast cancer 15 years after end of Malmo mammographic screening trial: follow-up study. BMJ. 2006; 332: 689–92.
    OpenUrlAbstract/FREE Full Text
  40. 40.
    2. Seigneurin A.
    Overdiagnosis from non-progressive cancer detected by screening mammography: stochastic simulation study with calibration to population based registry data. BMJ. 2011; 343: d7017.
    OpenUrlAbstract/FREE Full Text
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords